Long-term Evaluation of the Linox Family ICD Leads Registry (GALAXY)

NCT ID: NCT00836589

Last Updated: 2019-02-15

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1997 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-12-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to confirm the long-term safety and reliability of the Linox Lead System as used with BIOTRONIK ICDs. The GALAXY registry will provide data to fully characterize ICD lead failures, from implant through 5 years, including those failures contributing to patients losing pacing or defibrillation therapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a multi-center, prospective, non-randomized, 5-year data collection registry. Eligible patients must have been successfully implanted with a Linox Lead System connected to a BIOTRONIK ICD and consented and enrolled between 1-45 days following implant. This study is designed to be a post-implant (office-based) registry, and patients are meant to be seen according to each institution's standard of care, but not to exceed a follow-up time frame of every 6 months. At least 2000 patients will be enrolled in this registry, and each patient will be followed for five years post-implant.

Safety will be evaluated based on the analysis of the overall incidence of lead-related adverse events that require additional invasive intervention to resolve. In addition, each individual adverse event will be separately investigated. Lead parameters for sensing, pacing thresholds, and impedance will also be evaluated. An independent Clinical Events Committee will review and adjudicate all adverse events that occur during the study according to the protocol definitions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Patients Indicated for an ICD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Data Collection Group

ICD Therapy - ICD Lead Registry

Intervention Type DEVICE

Collecting long-term safety and efficacy data on a family of market-released ICD leads.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ICD Therapy - ICD Lead Registry

Collecting long-term safety and efficacy data on a family of market-released ICD leads.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Successfully implanted Linox Lead System connected to a BIOTRONIK ICD, from 1-45 days prior to enrollment
* Able to understand the nature of the registry and provide informed consent
* Available for follow-up visits on a regular basis at the investigational site
* Age greater than or equal to 18 years

Exclusion Criteria

* Enrolled in any IDE clinical study
* Planned cardiac surgical procedures or investigational measures within the next 6 months
* Expected to receive a heart transplant within 1 year
* Life expectancy less than 1 year
* Presence of another life-threatening, underlying illness separate from their cardiac disorder
* Pregnancy
* Inability to provide date of implant, devices implanted, age, gender, and whether the patient experienced any protocol-defined adverse events since implant
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Biotronik, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Albertville, Alabama, United States

Site Status

Birmingham, Alabama, United States

Site Status

Gadsden, Alabama, United States

Site Status

Jasper, Alabama, United States

Site Status

Glendale, Arizona, United States

Site Status

Mesa, Arizona, United States

Site Status

Phoenix, Arizona, United States

Site Status

Scottsdale, Arizona, United States

Site Status

Tucson, Arizona, United States

Site Status

Burbank, California, United States

Site Status

Fairfield, California, United States

Site Status

Fountain Valley, California, United States

Site Status

Glendale, California, United States

Site Status

Hawthorne, California, United States

Site Status

Inglewood, California, United States

Site Status

Los Angeles, California, United States

Site Status

Mission Viejo, California, United States

Site Status

Northridge, California, United States

Site Status

Rancho Mirage, California, United States

Site Status

Santa Barbara, California, United States

Site Status

Santa Maria, California, United States

Site Status

Torrance, California, United States

Site Status

Aurora, Colorado, United States

Site Status

Boulder, Colorado, United States

Site Status

Brooksville, Florida, United States

Site Status

Daytona Beach, Florida, United States

Site Status

Inverness, Florida, United States

Site Status

Jacksonville, Florida, United States

Site Status

Melbourne, Florida, United States

Site Status

Miami, Florida, United States

Site Status

Naples, Florida, United States

Site Status

New Smyrna Beach, Florida, United States

Site Status

Pensacola, Florida, United States

Site Status

Port Charlotte, Florida, United States

Site Status

Atlanta, Georgia, United States

Site Status

Alton, Illinois, United States

Site Status

Centralia, Illinois, United States

Site Status

Chicago, Illinois, United States

Site Status

Hammond, Indiana, United States

Site Status

Jeffersonville, Indiana, United States

Site Status

Owensboro, Kentucky, United States

Site Status

Lafayette, Louisiana, United States

Site Status

Lake Charles, Louisiana, United States

Site Status

Marrero, Louisiana, United States

Site Status

Baltimore, Maryland, United States

Site Status

Cumberland, Maryland, United States

Site Status

Rockville, Maryland, United States

Site Status

Salisbury, Maryland, United States

Site Status

Grand Rapids, Michigan, United States

Site Status

Ypsilanti, Michigan, United States

Site Status

Biloxi, Mississippi, United States

Site Status

Bridgeton, Missouri, United States

Site Status

Crystal City, Missouri, United States

Site Status

St Louis, Missouri, United States

Site Status

Haddon Heights, New Jersey, United States

Site Status

Rochester, New York, United States

Site Status

Charlotte, North Carolina, United States

Site Status

Concord, North Carolina, United States

Site Status

Gastonia, North Carolina, United States

Site Status

Greensboro, North Carolina, United States

Site Status

Grand Forks, North Dakota, United States

Site Status

Columbus, Ohio, United States

Site Status

Massillon, Ohio, United States

Site Status

Toledo, Ohio, United States

Site Status

Zanesville, Ohio, United States

Site Status

Salem, Oregon, United States

Site Status

Tualatin, Oregon, United States

Site Status

Chinchilla, Pennsylvania, United States

Site Status

Phoenixville, Pennsylvania, United States

Site Status

Yardley, Pennsylvania, United States

Site Status

Columbia, South Carolina, United States

Site Status

Florence, South Carolina, United States

Site Status

Greenville, South Carolina, United States

Site Status

Greenwood, South Carolina, United States

Site Status

Lancaster, South Carolina, United States

Site Status

Rock Hill, South Carolina, United States

Site Status

Chattanooga, Tennessee, United States

Site Status

Amarillo, Texas, United States

Site Status

El Paso, Texas, United States

Site Status

Fort Worth, Texas, United States

Site Status

Houston, Texas, United States

Site Status

Kingwood, Texas, United States

Site Status

McAllen, Texas, United States

Site Status

McKinney, Texas, United States

Site Status

Yakima, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Good ED, Cakulev I, Orlov MV, Hirsh D, Simeles J, Mohr K, Moll P, Bloom H. Long-Term Evaluation of Biotronik Linox and Linox(smart) Implantable Cardioverter Defibrillator Leads. J Cardiovasc Electrophysiol. 2016 Jun;27(6):735-42. doi: 10.1111/jce.12971. Epub 2016 May 3.

Reference Type DERIVED
PMID: 26990515 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GALAXY

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

ProMRI PROVEN Master Study
NCT01809665 COMPLETED